Pharma Boost: China+1 Strategy Gains Traction, But Complete Gains Still 2-3 Years Away
In a significant development reshaping global pharmaceutical manufacturing, the China+1 strategy is gaining substantial momentum. Major players across the pharma sector are realigning their production and sourcing strategies to reduce overdependence on China, particularly for active pharmaceutical ingredients (APIs). While the transition has been set in motion, full monetisation of this strategic shift is still…